JP2009256374A5 - - Google Patents

Download PDF

Info

Publication number
JP2009256374A5
JP2009256374A5 JP2009181759A JP2009181759A JP2009256374A5 JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5 JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009181759 A JP2009181759 A JP 2009181759A JP 2009256374 A5 JP2009256374 A5 JP 2009256374A5
Authority
JP
Japan
Prior art keywords
pharmaceutical formulation
stem cells
nitric oxide
oxide donor
formulation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009181759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009256374A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2009256374A publication Critical patent/JP2009256374A/ja
Publication of JP2009256374A5 publication Critical patent/JP2009256374A5/ja
Pending legal-status Critical Current

Links

JP2009181759A 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー Pending JP2009256374A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34547802P 2002-01-04 2002-01-04

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2003557275A Division JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Publications (2)

Publication Number Publication Date
JP2009256374A JP2009256374A (ja) 2009-11-05
JP2009256374A5 true JP2009256374A5 (enExample) 2010-09-16

Family

ID=23355218

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー
JP2009181759A Pending JP2009256374A (ja) 2002-01-04 2009-08-04 疾患および損傷の処置のための一酸化窒素ドナー

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2003557275A Expired - Fee Related JP4545440B2 (ja) 2002-01-04 2003-01-06 疾患および損傷の処置のための一酸化窒素ドナー

Country Status (9)

Country Link
US (2) US20050143388A1 (enExample)
EP (1) EP1469852A4 (enExample)
JP (2) JP4545440B2 (enExample)
CN (1) CN1638775A (enExample)
AU (1) AU2003210447B2 (enExample)
CA (1) CA2471147C (enExample)
IL (1) IL162850A0 (enExample)
WO (1) WO2003056899A2 (enExample)
ZA (1) ZA200405507B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010337A2 (de) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Verwendung von phosphodiesterase typ 5-hemmern für die prävention und behandlung von adipositas, sowie abgabesysteme für dieselben
JP2009521403A (ja) * 2005-11-14 2009-06-04 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク Ｍｒｉによる神経発生の相関の画像法
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
CN101754756A (zh) * 2007-05-18 2010-06-23 维瓦斯公司 包含磷酸二酯酶-5抑制剂的新组合和它们的用途
US20110104100A1 (en) * 2007-10-04 2011-05-05 Medistem Laboratories, Inc. Compositions and methods of stem cell therapy for autism
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
EA029892B1 (ru) 2012-04-25 2018-05-31 Такеда Фармасьютикал Компани Лимитед Азотсодержащее гетероциклическое соединение
JP6205356B2 (ja) 2012-07-13 2017-09-27 武田薬品工業株式会社 複素環化合物
ES2635016T3 (es) * 2013-03-01 2017-10-02 Fundación Para La Investigación Médica Aplicada Nuevos compuestos como inhibidores duales de fosfodiesterasas e histonas deacetilasas
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP3018126A4 (en) 2013-07-03 2016-12-07 Takeda Pharmaceuticals Co HETEROCYCLIC CONNECTION
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
US10297661B2 (en) * 2017-06-30 2019-05-21 Taiwan Semiconductor Manufacturing Co., Ltd. High voltage resistor device
WO2023109513A1 (zh) * 2021-12-14 2023-06-22 真奥金银花药业有限公司 爱地那非或其盐在制备预防或治疗缺血性脑损伤的药物中的应用
TWI879058B (zh) * 2023-08-31 2025-04-01 未來新藥股份有限公司 Pde5抑制劑組合於促進神經突生長之新穎用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI964113L (fi) * 1994-04-15 1996-10-14 Iyo Masaomi Lääkekoostumus hoitamaan tardiivia dyskinesiaa ja sen käyttö
US5827740A (en) * 1996-07-30 1998-10-27 Osiris Therapeutics, Inc. Adipogenic differentiation of human mesenchymal stem cells
CA2279651A1 (en) * 1996-09-05 1998-03-12 Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6043223A (en) * 1997-11-12 2000-03-28 The Regents Of The University Of California Enhanced opening of abnormal brain tissue capillaries
DE19834507A1 (de) * 1998-07-31 2000-02-03 Hexal Ag Pharmazeutische, wasserlösliche Tablettenformulierung zur Anwendung von Sildenafil
AU780994B2 (en) 1999-05-14 2005-04-28 Henry Ford Health System Bone marrow transplantation for treatment of stroke
IL147112A0 (en) * 1999-06-14 2002-08-14 Ford Henry Health System Nitric oxide donors for inducing neurogenesis
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
US6271228B1 (en) 2000-04-28 2001-08-07 Pfizer Inc. Blood pressure stabilization during hemodialysis
US7947731B2 (en) * 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training

Similar Documents

Publication Publication Date Title
JP2012255026A5 (enExample)
JP2010222367A5 (enExample)
JP2013518056A5 (enExample)
EP2364144A4 (en) PHARMACEUTICAL FORM FOR ADMINISTRATION THROUGH THE MOUTH
RU2600440C3 (ru) Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
JP2012500090A5 (enExample)
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
HRP20240168T1 (hr) Kombinacije dolutegravira i lamivudina za liječenje hiv infekcije
GEP20166488B (en) Co-crystals and salts of ccr3-inhibitors
JP2014532722A5 (enExample)
NZ593475A (en) Calcium salts for reducing exhalation of infectious bioaerosol particles
AR061166A1 (es) Composiciones farmaceuticas para la liberacion sostenida de fenilferina
RU2014142025A (ru) Препарат длительного высвобождения для снижения частоты мочеиспускания и способ его применения
MA32406B1 (fr) Composés contenant de l'azote tricyclique et utilisation de ceux-ci comme antibactériens
JP2012518646A5 (enExample)
JP2007238598A5 (enExample)
JP2013543518A5 (enExample)
WO2009084041A3 (en) Pharmaceutical compositions of dexibuprofen
JP2002537232A5 (enExample)
UY30126A1 (es) Una nueva sal farmaceuticamente aceptable de 2-hidroxi-3-(5-(morfolin-4-ilmetil)-piridin-2-l)1h-indol-5-carbonitrilo, procedimientos para su preparacion, composiciones que la contienen yaplicaciones
JP2011516572A5 (enExample)
JP2006342148A5 (enExample)
RU2011137413A (ru) Применение кардиотрофина-1 для лечения метаболических заболеваний
MX2008015323A (es) Composicion farmaceutica que comprende ciclobenzaprina y aceclofenac en asociacion.